Next 10 |
home / stock / capr / capr articles
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and ex...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exo...
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transfor...
Anthony Bergmann, Chief Financial Officer at Capricor Therapeutics (NASDAQ:CAPR), reported a large exercise of company stock options on October 24,...
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern aroun...
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around ...
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 wh...
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group ...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and ex...
2024-03-18 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month ...